Chinese rare diseases platform Citrine Medicine secures USD80m Series A round

On July 13, Chinese pharmaceutical company Citrine Medicine, which specializes in rare diseases, closed a 80 million US dollars Series A financing round.

On July 13, Chinese pharmaceutical company Citrine Medicine, which specializes in rare diseases, closed a 80 million US dollars Series A financing round.

This round of financing was led by Quan Capital, with participation from 3H Health Investment, Wu Capital, as well as three founding investors including Eight Roads Capital, F-Prime Capital and Vivo Capital.

Citrine Medicine is a Chinese pharmaceutical company focused on the treatment of rare diseases which focuses on providing clinically proven medicines to patients with rare diseases.

The company mainly uses Internet tools and big data analytics technology to build a patient-centric service platform for the entire rare disease community.

Lin Rui, a partner at Eight Roads Capital and member of the board of directors of Citrine Medicine, said that Citrine Medicine intends to introduce safe and effective rare disease drugs to Chinese patients.

The goal is to create a patient-centered rare disease ecosystem that addresses the root causes of access and affordability by working with various interested parties.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/20/chinese-rare-diseases-platform-citrine-medicine-secures-usd80m-series-a-round/.

Leave a Reply

Please Login to Comment